SCM
RCKT icon

Sterling Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Sterling Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24K Sell
1,823
-639
-26% -$2.13K ﹤0.01% 2494
2026
Q1 		$8.81K Sell
2,462
-1,762
-42% -$7K ﹤0.01% 2443
2025
Q4 		$14.8K Sell
4,224
-763
-15% -$2.61K ﹤0.01% 2394
2025
Q3 		$16.3K Buy
4,987
+3,036
+156% +$9.56K ﹤0.01% 2246
2025
Q2 		$4.78K Buy
1,951
+1,866
+2,195% +$9.45K ﹤0.01% 2538
2025
Q1 		$567 Buy
85
+17
+25% +$168 ﹤0.01% 2943
2024
Q4 		$855 Hold
68
– – ﹤0.01% 2974
2024
Q3 		$1.26K Buy
+68
New +$1.39K ﹤0.01% 2412

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sterling Capital Management's RCKT Position: Q2 2026 in Review

Sterling Capital Management reduced its Rocket Pharmaceuticals (RCKT) stake by 26% in Q2 2026, selling an estimated $2.13K and leaving 1,823 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

Sterling Capital Management first reported a position in RCKT in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.3K in Q3 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Sterling Capital Management held 1,823 shares of Rocket Pharmaceuticals worth $6.24K as of Q2 2026.
  • Sterling Capital Management sold 639 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.13K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2494 holding.
  • Sterling Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Rocket Pharmaceuticals position peaked at $16.3K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.